EntryPoint Capital LLC Has $279,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

EntryPoint Capital LLC increased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 277.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,913 shares of the biotechnology company’s stock after purchasing an additional 46,248 shares during the quarter. EntryPoint Capital LLC’s holdings in Ironwood Pharmaceuticals were worth $279,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IRWD. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Ironwood Pharmaceuticals by 150.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company’s stock worth $520,000 after buying an additional 75,917 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $181,000. Charles Schwab Investment Management Inc. increased its holdings in Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after purchasing an additional 364,841 shares in the last quarter. Daiwa Securities Group Inc. raised its position in Ironwood Pharmaceuticals by 21.2% in the 3rd quarter. Daiwa Securities Group Inc. now owns 67,570 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 11,800 shares during the last quarter. Finally, FMR LLC boosted its stake in Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock worth $699,000 after purchasing an additional 34,089 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on IRWD shares. JMP Securities cut their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Craig Hallum dropped their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD opened at $1.46 on Friday. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.34 and a 1-year high of $9.01. The stock has a market capitalization of $233.64 million, a P/E ratio of -48.67 and a beta of 0.37. The business has a 50-day moving average price of $2.09 and a two-hundred day moving average price of $3.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. As a group, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CMO Michael Shetzline sold 41,269 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 192,381 shares of company stock worth $338,591. Insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.